DAVID GILL

David N. Gill has over 30 years’ experience in senior operating and financial roles in the life sciences industry. He is the Chief Financial Officer of Perspectum, Ltd., a private medical imaging and diagnostics company based in the UK. Mr. Gill was most recently the President and Chief Financial Officer of EndoChoice Holdings, Inc., a publicly traded medical device company focused on gastroenterology products that was acquired in November 2016.  Earlier in his career, Mr. Gill served in a variety of senior executive leadership roles for several healthcare related companies, including INC Research (now known as Syneos), TransEnterix, NxStage Medical, CTI Molecular Imaging, Inc., Novoste Corporation and Dornier Medical Systems. He currently serves as a director of the following public companies: Y-mAbs Therapeutics, Evolus and Strongbridge Biopharma.